PCSK9 inhibitors are a new class of drugs that lower LDL, or “bad,” cholesterol. Right now, there are two FDA-approved medications: alirocumab (Praluent) and evolocumab (Repatha). These medications have also been used to successfully lower Lipoprotein(a). Administration is easy and must be done only once per month. Several studies indicate risk of heart attack has been reduced.
Lipid apheresis can significantly reduce lipoprotein(a) levels compared with available drug therapies, according to a presentation at National Lipid Association Scientific Sessions.